AstraZeneca ((AZN)), Parexel International ((PRXL)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
AstraZeneca, in collaboration with Parexel International, is conducting a study titled ‘An Open-label, Fixed-sequence and Two-part Study to Assess the Impact of Multiple Doses of Itraconazole on the Pharmacokinetics of AZD5004 in Healthy Participants and Multiple Doses of AZD5004 on the Pharmacokinetics of Combined Oral Ethinyl Oestradiol and Levonorgestrel in Healthy Female Participants.’ The study aims to evaluate how multiple doses of Itraconazole affect the pharmacokinetics of AZD5004 and how AZD5004 impacts the pharmacokinetics of combined oral contraceptives in healthy female participants. This research is significant as it could influence the development of new treatment protocols and drug interactions.
The study involves two main interventions: AZD5004, an oral tablet, and Itraconazole, an oral capsule, tested in Part A, and AZD5004 combined with Ethinyl Estradiol/Levonorgestrel (EE/LNG) in Part B. These interventions are designed to explore potential drug interactions and their effects on drug absorption and efficacy.
This interventional study is structured as an open-label, fixed-sequence, two-part trial. It is non-randomized with a sequential intervention model, focusing on treatment as the primary purpose. The study is conducted in Germany and the USA, with no masking involved, ensuring transparency in the results.
The study began on May 28, 2025, with the primary completion and estimated completion dates yet to be announced. The latest update was submitted on June 24, 2025. These dates are crucial for tracking the study’s progress and anticipating future updates.
The outcome of this study could have significant market implications for AstraZeneca and Parexel. Positive results may enhance investor confidence and potentially boost stock performance, while also impacting the competitive landscape within the pharmaceutical industry. Investors should monitor these developments closely as they could influence market dynamics.
The study is currently ongoing, with further details available on the ClinicalTrials portal.